KemPharm selects Johnson Matthey for API supply
Johnson Matthey is to manufacture the active pharmaceutical ingredient (API) in KP201, a pain drug developed by KemPharm, as part of a risk-and-reward sharing partnership.
KemPharm will retain responsibility for drug product, regulatory filings and preclinical and clinical studies, while Johnson Matthey will handle API production. Johnson Matthey was selected as a partner in part because of its experience of producing controlled drug substances.
"It is our belief that this risk-and-reward sharing partnership with Johnson Matthey signals an acknowledgement of the sizable upside potential in KP201”, added Kate Holt, senior director of business development for KemPharm.
Holt also believes the deal with Johnson Matthey further validates its proprietary ligand activated therapy (LAT) approach.
